



Antitumor activity of histamine and clozapine in a mouse experimental model of human melanoma

Noelia A. Massari^a, Vanina A. Medina^{a,b,*}, Graciela P. Cricco^a, Diego J. Martinel Lamas^a, Lorena Sambuco^c, Romina Pagotto^d, Clara Ventura^a, Pablo J. Ciralo^a, Omar Pignataro^d, Rosa M. Bergoc^{a,b}, Elena S. Rivera^{a,**}

^a Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires 1113, Argentina

^b National Scientific and Technical Research Council (Conicet), Buenos Aires, Argentina

^c Institute of Immunooncology, Buenos Aires, Argentina

^d Laboratory of Molecular Endocrinology and Signal Transduction, Institute of Biology and Experimental Medicine-Conicet, Buenos Aires 1428, Argentina

ARTICLE INFO

Article history:

Received 1 March 2013

Received in revised form 16 July 2013

Accepted 22 July 2013

We dedicate this work to the memory of our friend, colleague and excellent pathologist Maximo Croci, MD.

Keywords:

Histamine

H₄R

Melanoma

Survival

Proliferation

ERK1/2

ABSTRACT

Background: Functional presence of histamine H₄ receptor (H₄R) was demonstrated in human melanoma cell lines and biopsies.

Objective: The purposes of this work were to investigate signal transduction pathways and biological responses triggered by the activation of H₄R in human primary (WM35) and metastatic (M1/15) melanoma cell lines and to evaluate the *in vivo* antitumor activity of histamine (HA) and clozapine (CLZ) on human M1/15 melanoma xenografts.

Methods: Clonogenic assay, incorporation of BrdU, cell cycle distribution, phosphorylation levels of ERK1/2 and cAMP production were evaluated *in vitro*. An experimental human melanoma model was developed into athymic nude mice. Tumor growth, survival and histochemical studies were performed in order to investigate the expression levels of H₄R, HA, PCNA, mitotic index (MI), and angiogenesis.

Results: The results indicate that H₄R agonists inhibited forskolin-induced cAMP levels only in M1/15 cells while increased phosphorylation levels of ERK1/2 and decreased proliferation in both cell types. *In vivo* studies show that HA and CLZ (1 mg kg⁻¹, sc) significantly increased median survival and decreased tumor volume. These effects were associated to a reduction in MI, in the expression of proliferation marker and in intratumoral neovascularization.

Conclusions: We conclude that HA and CLZ exhibit an antitumoral effect *in vitro* and *in vivo* on human melanoma, suggesting the therapeutic potential of these compounds for the treatment of malignant melanoma.

© 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Melanoma accounts for less than 5% of skin cancer cases but causes a large majority of skin cancer deaths. Therefore, new therapeutic targets are urgently needed to improve the development of an effective systemic therapy.

Histamine (HA) has been implicated as one of the mediators involved in regulation of proliferation in both normal and neoplastic tissues. Melanoma cells but not normal melanocytes

contain large amounts of HA that has been found to accelerate malignant growth [1]. HA exerts its functions through binding to G protein-associated histamine H₁, H₂, H₃, H₄ receptors (H₁R, H₂R, H₃R, and H₄R), resulting in the activation of different signal transduction pathways [2–4]. It has been previously reported the expression of H₁R, H₂R and H₃R in human melanoma cell lines [5]. In human primary WM35 melanoma cells, HA acting through the H₁R decreases cell proliferation, whereas it enhances growth when acting through the H₂R [6], while stimulation of the H₃R in human melanoma cells did not show mitogenic signaling [5]. On the other hand, in highly metastatic M1/15 human melanoma cells HA produces a significant decrease in cell proliferation, effect that was mimicked by an H₁R agonist [6].

Numerous *in vivo* studies employing animal models bearing syngenic or xenogenic melanoma grafts demonstrated that both endogenous and exogenous histamine have the ability to stimulate tumor growth while H₂R antagonists inhibit this effect [1,7,8]. In

* Corresponding author at: Laboratorio de Radioisótopos, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina.

** Corresponding author at: Laboratorio de Radioisótopos, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires 1113, Argentina. Tel.: +54 11 4964 8277/8202; fax: +54 11 4964 8277/8202x31.

E-mail addresses: vmedina@ffybu.uba.ar, vaninamedina78@yahoo.com.ar (V.A. Medina), erivera@ffybu.uba.ar (E.S. Rivera).

agreement with these results, H₂R antagonists stimulated melanogenesis and inhibited proliferation in B16-C3 mouse melanoma cells [9]. It was also found that melanoma tumor growth was not modulated by *in vivo* HA treatment while treatment with terfenadine, an H₁R antagonist, significantly inhibited tumor growth *in vitro* and *in vivo* in murine melanoma models [10].

The latest identified member of the G protein-coupled histamine receptor subfamily was the H₄R with potential functional implications in inflammatory diseases and cancer [4,11,12]. H₄R describes distinct isoforms [13,14] and oligomeric structures resulting in diverse signaling pathways [2,14]. In recombinant systems activation of G_{i/o} proteins resulted in a decrease in adenylyl cyclase activity and consequently reduction in levels of cAMP within the cell [15,16]. However, in some cell-types, such as mouse mast cells, the endogenous H₄R has been shown to couple to Ca²⁺ mobilization in a pertussis toxin-sensitive manner, but not to cAMP [17]. Furthermore, there is growing evidence that where multiple pathways are activated by the same receptor, certain agonists are able to preferentially activate one pathway over another, displaying collateral efficacy [18].

The Ras/Raf/MEK/ERK (MAPK) pathway is among the most commonly deregulated pathways identified in tumors and there is no doubt that it is critical for melanoma development and progression, and a primary therapeutic target [19,20]. It was described that H₄R stimulation results in the pertussis-toxin-sensitive activation of downstream activated protein kinase pathways [2]. However, little is known about the signal transduction pathways associated to this receptor in cancer cells.

We have previously explored the expression of H₄R and some associated biological responses in human malignant melanoma cell lines (WM35 and M1/15). Results demonstrated that melanoma cells express H₄R at the mRNA and protein level. By using histamine agonists (VUF 8430 and clobenpropit), antagonists (JNJ7777120) and genetic tools (siRNA H₄R) it was shown that the inhibitory effect of HA on proliferation was in part mediated through the stimulation of the H₄R. Treatment with a specific H₄R antagonist and the use of siRNA specific for H₄R mRNA blocked the decrease in proliferation triggered by the H₄R agonists. Furthermore, the decrease in proliferation exerted by H₄R agonists was associated with a two-fold induction of cell senescence and an increase in melanogenesis that is a differentiation marker on these cells [21]. In addition, the H₄R was expressed in human melanoma biopsies, confirming that the H₄R was present not only in these cell lines but also in human melanoma tissue. H₄R was detected in 42% (8/19) of melanoma biopsies with different histopathological types, including superficial spreading, nodular and acral-lentiginous types and exhibited cytoplasmic localization [21].

Clozapine (CLZ) is an atypical antipsychotic drug primarily prescribed to patients who are unresponsive to or intolerant of conventional neuroleptics. CLZ has been shown to fully activate the H₄R, although it displays a moderate (submicromolar) affinity and several works support the idea to use CLZ as H₄R agonist *in vitro* and *in vivo* [16,22–25].

Based on the presented evidences, the aims of this work were to investigate the action of H₄R agonists *in vitro* on signal transduction pathways and cell proliferation, and to evaluate the *in vivo* effect of HA and CLZ on tumor growth, levels of cell proliferation markers and vascularization and also survival of human melanoma xenografts developed in nude mice.

2. Materials and methods

2.1. Chemicals

Histamine (HA), 2-(1H-imidazol-4-yl)ethanamine (Sigma Chemical Co., Missouri, USA); H₄R agonists: VUF 8430 (VUF),

2-[(aminoiminomethyl)amino]ethyl carbamimidothioic acid ester dihydrobromide (Tocris Bioscience, Ellisville, Missouri, USA); clozapine (CLZ), 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzoc[1,5]benzodiazepine (kindly provided by Fabra Laboratories S.A, Buenos Aires, Argentina); H₄R antagonist: JNJ7777120 (JNJ77), 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (Johnson & Johnson Pharmaceutical Research and Development, USA).

2.2. In vitro studies

2.2.1. Cell culture

The human melanoma cell lines WM35 (primary melanoma, radial growth phase) and M1/15 (derived from liver metastasis, radial and vertical growth phase) were kindly provided by Professor A. Falus (Budapest, Hungary). WM35 cells are non-tumorigenic in nude mice [26], while M1/15 cells are able to induce tumors in nude mice when are injected subcutaneously [7].

Cells were cultured in RPMI 1640 supplemented with 10% (v/v), FBS, 0.3 g l⁻¹ glutamine, and 0.04 g l⁻¹ gentamicin (all from Gibco BRL, Grand Island, NY, USA). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂.

2.2.2. Cell proliferation assays

For clonogenic assay, WM35 and M1/15 cells were seeded in six-well plates (1000 cells per well). Cells were treated with 0.01 to 10 μM of CLZ (diluted in 0.5% ethanol final concentration) and/or 10 μM of JNJ77. Cells were incubated for 7 days and then fixed with 10% (v/v) formaldehyde in PBS (Sigma Chemical Co., Missouri, USA) and stained with 1% (w/v) toluidine blue in 70% (v/v) ethanol. The clonogenic proliferation was evaluated by counting the colonies containing 50 cells or more and was expressed as a percentage of the untreated wells.

Quantification of cellular DNA synthesis was performed by BrdU (Sigma Chemical Co., Missouri, USA) incorporation. Cells were seeded into 12-well plates in culture medium (25 000 cells per well), and treated with 10 μM of CLZ and/or 10 μM of JNJ77 for 48 h. After that, BrdU (30 μM) was added into culture medium for 2 h. Cells were then washed twice with PBS and fixed for 15 min in 4% (v/v) formaldehyde in PBS. To denature the DNA into single-stranded molecules, cells were incubated with 3 N HCl, 1% Triton X-100 (v/v) in PBS for 15 min at room temperature. Cells were washed with 1 ml of 0.1 M Na₂B₄O₇ (Sigma Chemical Co., Missouri, USA), 1% Triton X-100 (v/v) in PBS, pH 8.5 to neutralize the acid. After blocking with 5% FBS (v/v) in PBS, cells were then incubated with anti-BrdU mouse monoclonal antibody diluted in the ratio of 1:100 in 1% bovine seroalbumine (w/v) in PBS. Cells were washed with PBS and further incubated for 30 min with 1:100 fluorescein isothiocyanate-conjugated antimouse IgG (Sigma Chemical Co., Missouri, USA) and 4-6-diamidino-2-phenylindole (Sigma Chemical Co.) at room temperature. Coverslips were mounted with Fluor-Save™ Reagent (Calbiochem, Darmstadt, Germany) and fluorescence was observed by epifluorescence using an Olympus BX50 microscope. Photography was carried out with a CoolSnap digital camera. At least 300 cells were scored for each determination. Pictures were taken at a 400X-fold magnification.

2.2.3. Senescence-associated β-galactosidase staining

Cells were seeded into 12-well plates in culture medium (25 000 cells per well) and were left untreated or treated with 10 μM CLZ and/or 10 μM JNJ77 for 48 h. Senescence-associated β-galactosidase-positive cells were detected using the method described by Dimri et al. [27] and also previously by us [21]. Briefly, cells were fixed and incubated at 37 °C for 8 h with 1 mg ml⁻¹ 5-bromo-4-chloro-indolyl-β-galactoside (USB Corp., USA) in an appropriate buffer. After incubation, cells were washed twice with PBS and counterstained with hematoxylin and the

Download English Version:

<https://daneshyari.com/en/article/3212915>

Download Persian Version:

<https://daneshyari.com/article/3212915>

[Daneshyari.com](https://daneshyari.com)